Royal Bank Of Canada Cuts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target decreased by Royal Bank Of Canada from $14.00 to $13.00 in a research report report published on Friday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on the company. Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Citizens Jmp reduced their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. TD Cowen started coverage on BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price on the stock. Cantor Fitzgerald raised their price target on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, December 29th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

BioCryst Pharmaceuticals Stock Down 1.3%

Shares of BCRX opened at $6.58 on Friday. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The company has a 50-day simple moving average of $7.28 and a 200-day simple moving average of $7.58. The company has a market capitalization of $1.39 billion, a PE ratio of -131.60, a P/E/G ratio of 0.38 and a beta of 0.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company had revenue of $159.40 million for the quarter, compared to analysts’ expectations of $162.91 million. During the same period in the prior year, the firm posted ($0.07) EPS. The firm’s quarterly revenue was up 36.1% on a year-over-year basis. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 91,004 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at $2,954,679.20. The trade was a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 183,453 shares of company stock valued at $1,330,965 over the last ninety days. Insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 36.1% in the 4th quarter. Sanctuary Advisors LLC now owns 58,571 shares of the biotechnology company’s stock valued at $457,000 after purchasing an additional 15,544 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after buying an additional 482,494 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the last quarter. Phocas Financial Corp. purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $1,956,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $115,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.